Presentation

Company Profile
Oblique Therapeutics AB is a privately held Swedish biotech company developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain and aggressive metastatic cancer. The company uses AbiProt®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. AbiProt®, is a proprietary methodology to identify epitopes on protein targets that have previously proven difficult to address with antibodies. AbiProt® can identify high-affinity antibody binding sites in a given protein with single amino acid resolution while the protein resides in its native environment. It is based on using a tailored molecular reporter system and proteomics. The platform yields detailed sequence and structure information for epitope identification and development. The company has 3 internal development programmes (OT-1096 in triple-negative breast cancer (TNBC), aTRPV1 and aTRPA1 in pain indications, and aKRAS in colorectal cancer). Two of these molecules are also developed in collaboration with undisclosed leading pharmaceutical companies for different indications. The company also has collaborations regarding two antibodies for type 2 diabetes, which are co-developed with a top-10 pharma through the AbiProt™ platform.

Recent highlights
In October 2020, Oblique Therapeutics was granted their first patent in respect of AbiProt. In November, the company raised SEK 98 million in a private placement investment round. In April 2021, the prestigious journal Science Advances published a research article describing the AbiProt™ technology, and more specifically the discovery and development of the antibodies targeting TRPV1 and KRAS.

Outlook
The company’s primary focus is to accelerate the development of its preclinical pipeline, while keeping attentive for potential collaborations with larger pharma players.